Abstract
Both management and prognosis vary with the many different varieties of non-Hodgkin's lymphoma. In large-cell disease, age and other risk factors influence prognosis. Relapses may respond to chemotherapy plus autologous bone marrow transplantation. Therapy with antibodies to tumor cells has made its debut, but its role remains unclear.
MeSH terms
-
Adult
-
Algorithms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Transplantation*
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Lymphoma, Non-Hodgkin / classification
-
Lymphoma, Non-Hodgkin / diagnosis*
-
Lymphoma, Non-Hodgkin / pathology
-
Lymphoma, Non-Hodgkin / therapy*
-
Prednisone / administration & dosage
-
Prognosis
-
Rituximab
-
Salvage Therapy*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone